Home » Stocks » Trevi Therapeutics

Trevi Therapeutics, Inc. (TRVI)

Stock Price: $3.50 USD 0.01 (0.29%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 63.84M
Revenue (ttm) n/a
Net Income (ttm) -29.76M
Shares Out 18.24M
EPS (ttm) -1.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $3.50
Previous Close $3.49
Change ($) 0.01
Change (%) 0.29%
Day's Open 3.50
Day's Range 3.37 - 3.52
Day's Volume 19,678
52-Week Range 1.33 - 8.50

More Stats

Market Cap 63.84M
Enterprise Value 19.97M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 18.24M
Float 2.88M
EPS (basic) -1.49
EPS (diluted) -1.66
FCF / Share -1.52
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 70,859
Short Ratio 1.78
Short % of Float 2.46%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.78
Revenue n/a
Operating Income -30.47M
Net Income -29.76M
Free Cash Flow -27.06M
Net Cash 43.87M
Net Cash / Share 2.41
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -31.18%
ROE -55.24%
ROIC 902.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$11.00*
(214.29% upside)
Low
9.00
Current: $3.50
High
13.00
Target: 11.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017
Revenue---
Operating Income-26.65-18.41-8.24
Net Income-26.05-20.55-12.86
Shares Outstanding11.740.440.42
Earnings Per Share-2.28-58.44-29.80
Operating Cash Flow-23.09-18.29-7.98
Capital Expenditures-0.01-0.16-0.01
Free Cash Flow-23.10-18.45-7.99
Cash & Equivalents57.317.2022.02
Total Debt0.360.055.29
Net Cash / Debt56.967.1616.74
Assets60.0010.5322.23
Liabilities5.46120107
Book Value54.55-109-84.43
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Trevi Therapeutics, Inc.
Country United States
Employees 19
CEO Jennifer L. Good

Stock Information

Ticker Symbol TRVI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TRVI
IPO Date May 7, 2019

Description

Trevi Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.